<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Canagliflozin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Canagliflozin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Canagliflozin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="88987" href="/d/html/88987.html" rel="external">see "Canagliflozin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16608644"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Invokana</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871596"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Invokana</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F16431883"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor;</li>
<li>
                        Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F16576226"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Correct hypovolemia, if present, prior to initiation. May require a gradual dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used as an adjunctive agent or alternative monotherapy for select patients, including those in whom initial therapy with lifestyle intervention and metformin failed<b>, or</b> who cannot take metformin. May be preferred in patients with atherosclerotic cardiovascular disease, heart failure, or diabetic kidney disease given demonstrated cardiovascular and renal benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1','lexi-content-ref-DeSantis.1','lexi-content-ref-28605608','lexi-content-ref-30990260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1','lexi-content-ref-DeSantis.1','lexi-content-ref-28605608','lexi-content-ref-30990260'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyperglycemia:</i>
<b>Oral:</b> Initial: 100 mg once daily prior to first meal of the day; may increase to 300 mg once daily after 4 to 12 weeks if needed to achieve glycemic goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DeSantis.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DeSantis.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Atherosclerotic cardiovascular disease: </i>
<b>Oral:</b> 100 or 300 mg once daily. <b>Note:</b> Risk reduction for major adverse cardiovascular events has been demonstrated in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28605608','lexi-content-ref-30424892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28605608','lexi-content-ref-30424892'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diabetic kidney disease:</i>
<b>Oral:</b> 100 mg once daily prior to the first meal of the day in patients with urinary albumin excretion &gt;300 mg/day; no further dose titration is necessary for renal benefit. <b>Note:</b> Some experts also use this regimen off label in patients <b>without</b> severely increased albuminuria (eg, urinary albumin excretion ≤300 mg/day); benefits and harms may be more closely balanced due to smaller absolute benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28605608','lexi-content-ref-Perkovic.1','lexi-content-ref-29937267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28605608','lexi-content-ref-Perkovic.1','lexi-content-ref-29937267'])">Ref</a></span>). Because sodium-glucose cotransporter 2 inhibitors have less glycemic benefit as eGFR declines, another agent may be needed to achieve glycemic goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990508"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: 100 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> with:</p>
<p style="text-indent:-2em;margin-left:6em;">Urinary albumin excretion &gt;300 mg/day: The manufacturer's labeling does not recommend initiation of therapy; however, patients previously established on canagliflozin may continue 100 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Urinary albumin excretion ≤300 mg/day: The manufacturer's labeling does not recommend initiation of therapy in patients <b>without</b> severely increased albuminuria. Canagliflozin should not be initiated in patients with an eGFR &lt;25 to 30 mL/minute/1.73 m<sup>2</sup>; in patients previously established on canagliflozin, some experts continue use off label at a dose of 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28605608','lexi-content-ref-29937267','lexi-content-ref-Perkovic.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28605608','lexi-content-ref-29937267','lexi-content-ref-Perkovic.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzable (highly protein bound): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987834"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild-to-moderate impairment (Child-Pugh class A, B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use not recommended (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F16576227"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56259475"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>acute kidney injury</b> (AKI) have been reported in patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors (specifically canagliflozin and dapagliflozin), including cases that have required hospitalization and dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>). While canagliflozin may cause reversible kidney-related adverse events (eg, <b>increased serum creatinine</b>, <b>decreased estimated GFR [eGFR]</b>) during the first weeks of therapy, an overall reduction in the risk of AKI and kidney-related serious adverse events was demonstrated in patients who received canagliflozin during the CREDENCE trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34029680','lexi-content-ref-32354987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34029680','lexi-content-ref-32354987'])">Ref</a></span>). As evidence mounts for the positive effects of these agents on long-term kidney outcomes and a possible reduction in the incidence of AKI, clinicians will need to weigh the potential risk of AKI with the overall benefit of these agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31050116','lexi-content-ref-34029680','lexi-content-ref-32354987','lexi-content-ref-28605608','lexi-content-ref-31495651','lexi-content-ref-28240446','lexi-content-ref-30415602']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31050116','lexi-content-ref-34029680','lexi-content-ref-32354987','lexi-content-ref-28605608','lexi-content-ref-31495651','lexi-content-ref-28240446','lexi-content-ref-30415602'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. SGLT2 inhibition causes increased excretion of glucose and sodium, thereby resulting in an osmotic diuresis; the subsequent hyperosmolarity and volume contraction may increase the risk of AKI. Glucose in the urine may be reabsorbed by glucose transporters in exchange for uric acid, resulting in uricosuria and associated crystal-dependent and -independent damage. Lastly, SGLT2 inhibition results in increased fructose generation; the metabolism of fructose may lead to increased uric acid, oxidative stress, and the release of chemokines, thus causing local tubular injury and inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31050116','lexi-content-ref-27847389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31050116','lexi-content-ref-27847389'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">On the other hand, canagliflozin may confer some protection against AKI. Proposed mechanisms based on animal studies regarding the beneficial effects of SGLT2 inhibition on AKI include improved kidney cortical oxygen tension, tubular cell integrity, and tubular albumin reabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26041448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26041448'])">Ref</a></span>); in addition, improved cardiac function may be related to improved kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32354987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32354987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied. With regard to decreases in eGFR, in the CREDENCE study, administration of canagliflozin caused early decline in eGFR which tended to stabilize after ~4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32354987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32354987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting risk factors for AKI (eg, hypovolemia, chronic kidney insufficiency, heart failure, use of concomitant medications [eg, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">An increased incidence of <b>bone fracture</b> was reported in the CANVAS clinical trial program (comprised of the CANVAS and CANVAS-R trials). The similarly designed CANVAS-R trial (n=5,812) did not show an increased fracture risk when analyzed separately from the CANVAS trial (n=4,330); reasons for these conflicting data within the CANVAS program are not clear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31399845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31399845'])">Ref</a></span>). Meta-analyses and pooled analyses (excluding CANVAS trial) have not demonstrated a risk of increased fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28440590','lexi-content-ref-27407013','lexi-content-ref-26580237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28440590','lexi-content-ref-27407013','lexi-content-ref-26580237'])">Ref</a></span>), and fracture risk was not increased in the CREDENCE trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30990260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30990260'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; fractures were observed as early as 12 weeks after treatment initiation in the CANVAS trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28605608','lexi-content-ref-26580237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28605608','lexi-content-ref-26580237'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Canagliflozin may cause <b>increased serum potassium</b>. In the CREDENCE trial, use of canagliflozin 100 mg daily in patients with a mean eGFR ~56 ± 18 mL/minute/1.73 m<sup>2</sup> did not increase the risk of hyperkalemia compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30990260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30990260'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24786834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24786834'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (eg, 300 mg daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24786834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24786834'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24786834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24786834'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, including <b>angioedema</b>, urticaria, <b>anaphylaxis</b> and skin rash, have been reported in patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established. Multiple potential mechanisms including:</p>
<p style="text-indent:-2em;margin-left:6em;">• Non–dose-related; immunologic: IgE-mediated or direct mast cell stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose-related; related to the pharmacologic action: Elevated levels of bradykinin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9734886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9734886'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; generally occurs hours to days after treatment initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prior serious hypersensitivity reaction to canagliflozin</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Although other SGLT2 have also been associated with hypersensitivity reactions, there are no reports of cross-reactions between these agents</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension/volume depletion</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sodium-glucose cotransporter 2 (SGLT2) inhibitors may cause events consistent with <b>hypovolemia</b>, including symptomatic <b>hypotension</b>, syncope, and dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27822054','lexi-content-ref-24786834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27822054','lexi-content-ref-24786834'])">Ref</a></span>). Overall, a reduction in both systolic and diastolic blood pressure (-4 to -6/-1 to -2 mm Hg) has been documented for SGLT2 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590','lexi-content-ref-28546454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590','lexi-content-ref-28546454'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Inhibition of SGLT2 causes an increase in the excretion of glucose and sodium, thereby resulting in an osmotic diuresis and intravascular volume contraction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28546454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28546454'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; timing is impacted by volume status (eg, reduced oral intake, fluid losses) and concomitant use of medications known to impact volume status or blood pressure (eg, diuretics, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (ie, eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of antihypertensives (eg, diuretics, ACE inhibitors, ARBs)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting low systolic blood pressure</p>
<p style="text-indent:-2em;margin-left:6em;">• Reduced oral intake or increased fluid losses</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including canagliflozin, have been associated with an increased risk of <b>genitourinary fungal infection</b> (eg, vulvovaginal mycotic infection, vulvovaginal candidiasis, vulvovaginitis, candida balanitis, balanoposthitis) and, to a lesser extent, urinary tract infections, including severe cases of urinary tract infection with sepsis and pyelonephritis requiring hospitalization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30207042','lexi-content-ref-32808541','lexi-content-ref-27862830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30207042','lexi-content-ref-32808541','lexi-content-ref-27862830'])">Ref</a></span>). These events are generally mild in intensity, respond to treatment, and do not lead to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26982554','lexi-content-ref-32808541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26982554','lexi-content-ref-32808541'])">Ref</a></span>). Additionally, rare but serious and potentially fatal cases of <b>necrotizing fasciitis</b> (perineum) (ie, Fournier gangrene) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31060053','lexi-content-ref-FDA.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31060053','lexi-content-ref-FDA.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Patients with diabetes are more prone to urinary tract and genital infections, potentially due to glucosuria-induced bacterial growth, increased adherence of bacteria to the uroepithelium, and altered immune function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24529566','lexi-content-ref-28888425','lexi-content-ref-23748505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24529566','lexi-content-ref-28888425','lexi-content-ref-23748505'])">Ref</a></span>). Because SGLT2 inhibitors increase urinary excretion of glucose, it has been hypothesized that these agents further increase the risk of these infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24529566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24529566'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; available literature suggests that the increased risk of genital infection may be apparent within the first month of SGLT2 inhibitor therapy and remain elevated throughout the course of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30207042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30207042'])">Ref</a></span>); Fournier gangrene may have an average onset of 9 months (range: 5 days to 49 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31060053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31060053'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes and/or uncontrolled hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28888425','lexi-content-ref-23748505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28888425','lexi-content-ref-23748505'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of these types of infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32808541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32808541'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32808541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32808541'])">Ref</a></span>)</p>
<p style="text-indent:0em;margin-left:4em;">• Uncircumcised males (increased risk for genital infections) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23748505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23748505'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ketoacidosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>ketoacidosis</b> have been reported in patients with type 1 and type 2 diabetes mellitus receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors, including canagliflozin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28736981','lexi-content-ref-FDA.3','lexi-content-ref-26294774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28736981','lexi-content-ref-FDA.3','lexi-content-ref-26294774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">In some cases, patients have presented with normal or only modestly elevated blood glucose (&lt;250 mg/dL), which can lead to misdiagnosis, prevent timely initiation of treatment, and negatively influence duration of illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30728224','lexi-content-ref-28797889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30728224','lexi-content-ref-28797889'])">Ref</a></span>). In addition, SGLT2 inhibitor-mediated increases in urinary glucose loss may persist for several days after discontinuation which may impact duration of illness in patients who develop ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Several mechanisms have been proposed centered on increased ketone body production and reabsorption. Because SGLT2 inhibitors decrease urinary excretion of ketone bodies and decrease blood glucose in an insulin-independent manner, plasma glucose and urine ketone concentrations may be lower than what is typically expected in classic presentations of diabetic ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665','lexi-content-ref-26086329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665','lexi-content-ref-26086329'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; timing is often impacted by the onset of metabolically stressful events (eg, surgery, extensive exercise, myocardial infarction [MI], stroke, severe infections, prolonged fasting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590','lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590','lexi-content-ref-27082665'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with diabetes who are insulin deficient (eg, latent autoimmune diabetes in adults, type 1 diabetes, or some patients with long-standing type 2 diabetes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Metabolically stressful events (eg, surgery, extensive exercise, MI, stroke, severe infections, prolonged fasting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665','lexi-content-ref-31081590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665','lexi-content-ref-31081590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of other risk factors that may predispose a patient to ketoacidosis (eg, pancreatitis, dose decreases of insulin, caloric restriction, ketogenic diet, alcohol abuse, acute febrile illness, volume depletion, surgery)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lower limb amputation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There are conflicting data involving the risk of lower limb amputations with sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy; canagliflozin, specifically, has been of concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32436638','lexi-content-ref-30105373','lexi-content-ref-FDA.2','lexi-content-ref-29430814','lexi-content-ref-30429124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32436638','lexi-content-ref-30105373','lexi-content-ref-FDA.2','lexi-content-ref-29430814','lexi-content-ref-30429124'])">Ref</a></span>). Canagliflozin was associated with almost a 2-fold increased risk of lower limb amputations compared to placebo in the CANVAS and CANVAS-R trials, which included patients with type 2 diabetes at high cardiovascular risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.5','lexi-content-ref-30868176','lexi-content-ref-28605608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.5','lexi-content-ref-30868176','lexi-content-ref-28605608'])">Ref</a></span>). However, no difference between placebo and canagliflozin was observed in the CREDENCE trial with regards to amputation risk; although the trial was terminated early due to kidney and cardiovascular benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2','lexi-content-ref-30990260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2','lexi-content-ref-30990260'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">During the CANVAS and CANVAS-R trials, amputations observed involved the toe, midfoot, or less frequently the leg (above or below the knee); lower limb infections, gangrene, and diabetic foot ulcers were the most common precipitating factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.5','lexi-content-ref-30868176','lexi-content-ref-28605608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.5','lexi-content-ref-30868176','lexi-content-ref-28605608'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32436638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32436638'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:4em;">• Preexisting risk factors for amputation (eg, prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcers, cardiovascular disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.5','lexi-content-ref-32843476','lexi-content-ref-28605608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.5','lexi-content-ref-32843476','lexi-content-ref-28605608'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32843476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32843476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">• Lack of preventative foot care</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F16576151"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Infection: Genitourinary fungal infection (females: 11% to 12%; males: 4%; patients who developed infections were more likely to experience recurrence)<span class="lexi-table-link-container"> (<a aria-label="Genitourinary Fungal Infection table link" class="lexi-table-link" data-table-id="lexi-content-genitourinary-fungal-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-genitourinary-fungal-infection')">table 1</a>)</span><span class="table-link" style="display:none;">Genitourinary Fungal Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Genitourinary Fungal Infection" frame="border" id="lexi-content-genitourinary-fungal-infection" rules="all">
<caption style="text-align:center;">
<b>Canagliflozin: Adverse Reaction: Genitourinary Fungal Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Canagliflozin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (3%)<span class="lexi-table-link-container"> (<a aria-label="Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypotension')">table 2</a>)</span><span class="table-link" style="display:none;">Hypotension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypotension" frame="border" id="lexi-content-hypotension" rules="all">
<caption style="text-align:center;">
<b>Canagliflozin: Adverse Reaction: Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Canagliflozin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">In patients with type 2 diabetes mellitus and diabetic nephropathy with albuminuria</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (4%), hypovolemia (2% to 3%)<span class="lexi-table-link-container"> (<a aria-label="Hypovolemia table link" class="lexi-table-link" data-table-id="lexi-content-hypovolemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypovolemia')">table 3</a>)</span><span class="table-link" style="display:none;">Hypovolemia</span>, increased serum potassium (eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>: &gt;5.4 mEq/L: 5% to 9%; ≥6.5 mEq/L: 1%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Potassium table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-potassium" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-potassium')">table 4</a>)</span><span class="table-link" style="display:none;">Increased Serum Potassium</span>, increased thirst (2% to 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypovolemia" frame="border" id="lexi-content-hypovolemia" rules="all">
<caption style="text-align:center;">
<b>Canagliflozin: Adverse Reaction: Hypovolemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Canagliflozin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo and Active Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Potassium" frame="border" id="lexi-content-increased-serum-potassium" rules="all">
<caption style="text-align:center;">
<b>Canagliflozin: Adverse Reaction: Increased Serum Potassium</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Canagliflozin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patient population: eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>; increased serum potassium defined as increases in serum potassium to &gt;5.4 mEq/L and 15% above baseline</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patient population: eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>; increased serum potassium defined as increases in serum potassium to &gt;5.4 mEq/L and 15% above baseline</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patient population: eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>; increased serum potassium defined as increases in serum potassium to ≥6.5 mEq/L</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glycemic control</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patient population: eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>; increased serum potassium defined as increases in serum potassium to ≥6.5 mEq/L</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), constipation (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Increased urine output (5%), urinary tract infection (6%), vulvovaginal pruritus (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased hemoglobin (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (4%; severe hypersensitivity reaction: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (1%), falling (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb injury (toe, foot, lower limb amputations: 2% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Phimosis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Increased LDL cholesterol, increased serum cholesterol (non-HDL)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (Vasapollo 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (Marsi 2021), ketoacidosis (Sloan 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection with sepsis (Gupta 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Necrotizing fasciitis (perineum) (Elbeddini 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Zhou 2019), decreased bone mineral density (Fralick 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Phadke 2020), decreased estimated GFR (eGFR) (FDA 2016), increased serum creatinine (FDA 2016), pyelonephritis (Gupta 2018)</p></div>
<div class="block coi drugH1Div" id="F16576099"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Serious hypersensitivity (eg, anaphylaxis, angioedema) to canagliflozin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F16576127"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery (Mechanick 2020; Melissas 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">– Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy and closely monitor the patient for the duration of therapy; volume depletion and related adverse events (eg, hypotension, orthostatic hypotension, syncope) have occurred. Fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">– Euglycemic diabetic ketoacidosis: Discontinue therapy 3 to 5 days prior to surgery (Bobart 2016). Postoperatively, assess volume status, caloric intake, and need for diabetes treatment and withhold antidiabetic medication if type 2 diabetes is in remission. Ketoacidosis has been reported in patients with type 1 and type 2 diabetes on SGLT2 inhibitors. In some cases, normal or only modestly elevated blood glucose was present (&lt;250 mg/dL) (van Niekerk 2018). Risk factors include significant reduction in insulin, caloric restriction, stress of surgery, and infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection, acute: Discontinue therapy if any of the following occur: signs and symptoms of new infection (including osteomyelitis), new pain or tenderness, or sores/ulcers involving the lower limbs (FDA Safety Communication 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Glycemic efficacy may be decreased in renal impairment. Dosage adjustment may be required, see "Dosing: Altered Kidney Function" for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age may have an increased risk of symptoms related to intravascular volume depletion (eg, hypotension, orthostatic hypotension, dizziness, syncope, and dehydration) during therapy, especially with the 300 mg dose; patients ≥75 years of age may experience a more pronounced risk. HbA<sub>1c</sub> reductions may be less in patients &gt;65 years of age compared to younger patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in patients with diabetic ketoacidosis <b>or</b> for glycemic control in patients with type 1 diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Use of SGLT2 inhibitors is not routinely recommended for glycemic control in hospitalized patients (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical procedures: Consider temporary discontinuation of therapy at least 3 days prior to surgery; ensure risk factors for ketoacidosis are resolved prior to reinitiating therapy.</p></div>
<div class="block foc drugH1Div" id="F16608645"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invokana: 100 mg, 300 mg</p></div>
<div class="block geq drugH1Div" id="F17918122"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F20319334"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Invokana Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $23.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $23.94</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871597"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invokana: 100 mg, 300 mg</p></div>
<div class="block adm drugH1Div" id="F16576242"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May be administered with or without food. It is recommended to take before the first meal of the day (may reduce postprandial hyperglycemia via delayed intestinal glucose absorption).</p></div>
<div class="block meg drugH1Div" id="F16576085"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F204042s040lbl.pdf%23page%3D47&amp;token=kJRNh0Xh2ji6Bq7P2Ej%2FUFO3M%2FRPBr2iuHkvFdgr2n2SBdmZGlMMcpm%2FYLjebJnpNnVlxt84y0D9VyXbvj6Zc6SGhSXVCSYsBT9X4VBB3ECi2CpCtxPma0ipgdG2MIjF&amp;TOPIC_ID=88901" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204042s040lbl.pdf#page=47</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F16431885"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, type 2, treatment:</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; risk reduction of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease; risk reduction of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with urinary albumin excretion &gt;300 mg/day.</p></div>
<div class="block mst drugH1Div" id="F58633711"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to increased risk of urogenital infections, especially in women during the first month of use. In addition, a higher risk of euglycemic diabetic ketoacidosis has been observed in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F17917889"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), MRP2, P-glycoprotein/ABCB1 (minor), UGT1A9, UGT2B4; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F17917887"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Canagliflozin may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Insulins.  Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Canagliflozin may enhance the hypotensive effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Canagliflozin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56092163"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Sodium-glucose cotransporter 2 (SGLT2) inhibitors are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)</p></div>
<div class="block pri drugH1Div" id="F16576096"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Due to adverse effects on renal development observed in animal studies, the manufacturer does not recommend use of canagliflozin during the second and third trimesters of pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than canagliflozin are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).</p></div>
<div class="block brc drugH1Div" id="F16576098"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if canagliflozin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block dic drugH1Div" id="F16576193"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>
<div class="block mop drugH1Div" id="F16576244"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Blood glucose; renal function (baseline and as clinically needed, especially in patients with preexisting renal impairment); volume status (eg, BP, hematocrit, electrolytes; baseline and periodically during treatment); serum potassium (periodically after initiation in renal impairment and those predisposed to hyperkalemia); genital mycotic infections and urinary tract infection; signs/symptoms of necrotizing fasciitis (eg, fever and malaise along with genital or perianal pain, tenderness, erythema, or swelling), hypersensitivity reactions; BP; lower limb and feet (sores, ulcers, infection); if signs/symptoms of ketoacidosis (eg, nausea/vomiting, abdominal pain, malaise, shortness of breath), confirm diagnosis by direct measurement of blood ketones and arterial pH (measurement of serum bicarbonate or urinary ketones may not be adequate) (AACE [Handelsman 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">HbA<sub>1c</sub>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F16576248"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (AACE [Samson 2023]; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:8em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note: </b>Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:8em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:8em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F16576191"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">By inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, canagliflozin reduces reabsorption of filtered glucose from the tubular lumen and lowers the renal threshold for glucose (RT<sub>G</sub>). SGLT2 is the main site of filtered glucose reabsorption; reduction of filtered glucose reabsorption and lowering of RT<sub>G</sub> result in increased urinary excretion of glucose, thereby reducing plasma glucose concentrations.</p></div>
<div class="block phk drugH1Div" id="F16576209"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Within 24 hours (dose-dependent)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Suppression of the renal threshold for glucose (RT<sub>G</sub>) occurs throughout the 24-hour dosing interval; maximal RT<sub>G</sub> suppression occurred with the 300 mg dose (RT<sub>G</sub> decreased from baseline of ~240 mg/dL to a mean of 70 to 90 mg/dL over 24 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Not affected by food; however, administration prior to the first meal of the day may delay intestinal glucose absorption, thereby reducing postprandial hyperglycemia.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 83.5 L (intravenous administration)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99% mainly to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Major metabolism through <i>O</i>-glucuronidation by UGT1A9 and UGT2B4 to two inactive metabolites; minor oxidative metabolism (~7%) through CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~65%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Apparent terminal half-life: 100 mg dose: 10.6 hours; 300 mg dose: 13.1 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (41.5% as unchanged drug, 7% as hydroxylated metabolite, 3.2% as <i>O</i>-glucuronide metabolite); urine ~33% (30.5% as <i>O</i>-glucuronide metabolites, &lt;1% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23777314"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Canaglif | Canarol | Diacana | Glicana</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Invokana | Motivyst | Prominad | Sulisent</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Canaglu</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Likana</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Invokana</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Canaglu</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26982554">
<a name="26982554"></a>Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. <i>Postgrad Med</i>. 2016;128(4):409-417. doi:10.1080/00325481.2016.1167570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/26982554/pubmed" id="26982554" target="_blank">26982554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32436638">
<a name="32436638"></a>Arnott C, Huang Y, Neuen BL, et al. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. <i>Diabetes Obes Metab</i>. 2020;22(10):1753-1766. doi:10.1111/dom.14091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/32436638/pubmed" id="32436638" target="_blank">32436638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31060053">
<a name="31060053"></a>Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. <i>Ann Intern Med</i>. 2019;170(11):764-769. doi:10.7326/M19-0085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/31060053/pubmed" id="31060053" target="_blank">31060053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28736981">
<a name="28736981"></a>Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. <i>Diabetes Metab Res Rev</i>. 2017;33(8):10.1002/dmrr.2924. doi:10.1002/dmrr.2924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/28736981/pubmed" id="28736981" target="_blank">28736981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27699391">
<a name="27699391"></a>Bobart SA, Gleason B, Martinez N, Norris K, Williams SF. Euglycemic ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors: a case report. <i>Ann Intern Med</i>. 2016;165(7):530-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/27699391/pubmed" id="27699391" target="_blank">27699391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30105373">
<a name="30105373"></a>Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. <i>JAMA Intern Med</i>. 2018;178(9):1190-1198. doi:10.1001/jamainternmed.2018.3034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30105373/pubmed" id="30105373" target="_blank">30105373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30728224">
<a name="30728224"></a>Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. <i>Diabetes Care</i>. 2019;42(6):1147-1154. doi:10.2337/dc18-2316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30728224/pubmed" id="30728224" target="_blank">30728224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30207042">
<a name="30207042"></a>Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. <i>Diabetes Obes Metab</i>. 2019;21(2):434-438. doi:10.1111/dom.13531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30207042/pubmed" id="30207042" target="_blank">30207042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DeSantis.1">
<a name="DeSantis.1"></a>DeSantis A. Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28797889">
<a name="28797889"></a>Dizon S, Keely EJ, Malcolm J, Arnaout A. Insights into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: it's not just euglycemic diabetic ketoacidosis. <i>Can J Diabetes</i>. 2017;41(5):499-503. doi:10.1016/j.jcjd.2017.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/28797889/pubmed" id="28797889" target="_blank">28797889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32089542">
<a name="32089542"></a>Elbeddini A, Gallinger J, Davey M, et al. A case of Fournier's gangrene in a patient taking canagliflozin for the treatment of type II diabetes mellitus. <i>Am J Case Rep</i>. 2020;21:e920115. doi:10.12659/AJCR.920115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/32089542/pubmed" id="32089542" target="_blank">32089542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35097199">
<a name="35097199"></a>El Masri D, Jamil Y, Eid Fares J. Sodium-glucose co-transporter protein 2 inhibitors induced hypercalcemia: a case series and literature review. <i>AACE Clin Case Rep</i>. 2021;8(1):30-33. doi:10.1016/j.aace.2021.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/35097199/pubmed" id="35097199" target="_blank">35097199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32808541">
<a name="32808541"></a>Engelhardt K, Ferguson M, Rosselli JL. Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors. <i>Ann Pharmacother</i>. 2021;55(4):543-548. doi:10.1177/1060028020951928<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/32808541/pubmed" id="32808541" target="_blank">32808541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.dor">
<a name="expert.dor"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Food and Drug Administration. Published August 26, 2020. Updated September 2, 2020. Accessed October 11, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.3">
<a name="FDA.3"></a>FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Food and Drug Administration. Published December 4, 2015. Updated March 19, 2020. Accessed October 11, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.4">
<a name="FDA.4"></a>FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Food and Drug Administration. Published August 29, 2018. Updated September 7, 2018. Accessed October 11, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31081590">
<a name="31081590"></a>Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. <i>Diabetes Obes Metab</i>. 2019;21 Suppl 2:34-42. doi:10.1111/dom.13611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/31081590/pubmed" id="31081590" target="_blank">31081590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32843476">
<a name="32843476"></a>Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. <i>BMJ</i>. 2020;370:m2812. Published 2020 Aug 25. doi:10.1136/bmj.m2812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/32843476/pubmed" id="32843476" target="_blank">32843476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30597484">
<a name="30597484"></a>Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fracture risk after initiation of use of canagliflozin: a cohort study. <i>Ann Intern Med</i>. 2019;170(3):155-163. doi:10.7326/M18-0567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30597484/pubmed" id="30597484" target="_blank">30597484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24529566">
<a name="24529566"></a>Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. <i>Diabetes Res Clin Pract</i>. 2014;103(3):373-381. doi:10.1016/j.diabres.2013.12.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/24529566/pubmed" id="24529566" target="_blank">24529566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31050116">
<a name="31050116"></a>Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. <i>Diabetes Obes Metab</i>. 2019;21(8):1996-2000. doi:10.1111/dom.13754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/31050116/pubmed" id="31050116" target="_blank">31050116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30573559">
<a name="30573559"></a>Gupta R, Ghosh A, Misra A. Case of acute unilateral emphysematous pyelonephritis and bacteraemia on treatment with canagliflozin. <i>Postgrad Med J</i>. 2018;94(1118):714-715. doi:10.1136/postgradmedj-2018-136109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30573559/pubmed" id="30573559" target="_blank">30573559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27847389">
<a name="27847389"></a>Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. <i>Nat Rev Nephrol</i>. 2016;12(12):711-712. doi:10.1038/nrneph.2016.159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/27847389/pubmed" id="27847389" target="_blank">27847389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27082665">
<a name="27082665"></a>Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. <i>Endocr Pract</i>. 2016;22(6):753-762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/27082665/pubmed" id="27082665" target="_blank">27082665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34029680">
<a name="34029680"></a>Heerspink HJL, Oshima M, Zhang H, et al. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial. <i>Am J Kidney Dis</i>. Published online May 23, 2021. doi:10.1053/j.ajkd.2021.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/34029680/pubmed" id="34029680" target="_blank">34029680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Invokana.1">
<a name="Invokana.1"></a>Invokana (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32354987">
<a name="32354987"></a>Jardine MJ, Zhou Z, Mahaffey KW, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. <i>J Am Soc Nephrol</i>. 2020;31(5):1128-1139. doi:10.1681/ASN.2019111168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/32354987/pubmed" id="32354987" target="_blank">32354987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29430814">
<a name="29430814"></a>Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? <i>Diabetes Obes Metab</i>. 2018;20(6):1531-1534. doi:10.1111/dom.13255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/29430814/pubmed" id="29430814" target="_blank">29430814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(supp 4):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27862830">
<a name="27862830"></a>Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. <i>Diabetes Obes Metab</i>. 2017;19(3):348-355. doi:10.1111/dom.12825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/27862830/pubmed" id="27862830" target="_blank">27862830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30868176">
<a name="30868176"></a>Matthews DR, Li Q, Perkovic V, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program. <i>Diabetologia</i>. 2019;62(6):926-938. doi:10.1007/s00125-019-4839-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30868176/pubmed" id="30868176" target="_blank">30868176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28546454">
<a name="28546454"></a>Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22,528 patients. <i>J Am Heart Assoc</i>. 2017;6(6):e004007. doi:10.1161/JAHA.116.004007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/28546454/pubmed" id="28546454" target="_blank">28546454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160151">
<a name="23160151"></a>Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. <i>Ann Surg</i>. 2013;258(6):976-982. doi:10.1097/SLA.0b013e3182774522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/23160151/pubmed" id="23160151" target="_blank">23160151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.5">
<a name="FDA.5"></a>Navin L. <i>FDA Drug Safety Podcast.</i> FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). May 26, 2017. Accessed October 11, 2021. <a href="https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine" target="_blank">https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28605608">
<a name="28605608"></a>Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med</i>. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/28605608/pubmed" id="28605608" target="_blank">28605608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495651">
<a name="31495651"></a>Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis [published correction appears in <i>Lancet Diabetes Endocrinol</i>. 2019;7(12):e23]. <i>Lancet Diabetes Endocrinol</i>. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/31495651/pubmed" id="31495651" target="_blank">31495651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888425">
<a name="28888425"></a>Nichols GA, Brodovicz KG, Kimes TM, Déruaz-Luyet A, Bartels DB. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. <i>J Diabetes Complications</i>. 2017;31(11):1587-1591. doi:10.1016/j.jdiacomp.2017.07.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/28888425/pubmed" id="28888425" target="_blank">28888425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9734886">
<a name="9734886"></a>Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. <i>Lancet</i>. 1998;351(9117):1693-1697. doi:10.1016/S0140-6736(97)09137-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/9734886/pubmed" id="9734886" target="_blank">9734886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23748505">
<a name="23748505"></a>Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. <i>Postgrad Med</i>. 2013;125(3):33-46. doi:10.3810/pgm.2013.05.2650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/23748505/pubmed" id="23748505" target="_blank">23748505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26041448">
<a name="26041448"></a>O'Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. <i>Am J Physiol Renal Physiol</i>. 2015;309(3):F227-F234. doi:10.1152/ajprenal.00689.2014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/26041448/pubmed" id="26041448" target="_blank">26041448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perkovic.1">
<a name="Perkovic.1"></a>Perkovic V, Badve SV, Bakris GL. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29937267">
<a name="29937267"></a>Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. <i>Lancet Diabetes Endocrinol</i>. 2018;6(9):691‐704. doi:10.1016/S2213-8587(18)30141-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/29937267/pubmed" id="29937267" target="_blank">29937267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30990260">
<a name="30990260"></a>Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. <i>N Engl J Med</i>. 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30990260/pubmed" id="30990260" target="_blank">30990260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32387022">
<a name="32387022"></a>Phadke G, Kaushal A, Tolan DR, et al. Osmotic nephrosis and acute kidney injury associated with SGLT2 inhibitor use: a case report. <i>Am J Kidney Dis</i>. 2020;76(1):144-147. doi:10.1053/j.ajkd.2020.01.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/32387022/pubmed" id="32387022" target="_blank">32387022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27822054">
<a name="27822054"></a>Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. <i>Vasc Health Risk Manag</i>. 2016;12:393-405. doi:10.2147/VHRM.S111991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/27822054/pubmed" id="27822054" target="_blank">27822054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26294774">
<a name="26294774"></a>Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. <i>Diabetes Care</i>. 2015;38(9):1638-1642. doi:10.2337/dc15-1380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/26294774/pubmed" id="26294774" target="_blank">26294774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440590">
<a name="28440590"></a>Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. <i>Diabetes Metab Res Rev</i>. 2017;33(6). doi:10.1002/dmrr.2903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/28440590/pubmed" id="28440590" target="_blank">28440590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16644645">
<a name="16644645"></a>Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and early childhood overweight in children from mothers with gestational diabetes mellitus. <i>Diabetes Care</i>. 2006;29(5):1105-1107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/16644645/pubmed" id="16644645" target="_blank">16644645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29899991">
<a name="29899991"></a>Sloan G, Kakoudaki T, Ranjan N. Prolonged diabetic ketoacidosis associated with canagliflozin. <i>Endocrinol Diabetes Metab Case Rep</i>. 2018;2018:17-0177. doi:10.1530/EDM-17-0177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/29899991/pubmed" id="29899991" target="_blank">29899991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28240446">
<a name="28240446"></a>Tang H, Li D, Zhang J, et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials. <i>Diabetes Obes Metab</i>. 2017;19(8):1106-1115. doi:10.1111/dom.12917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/28240446/pubmed" id="28240446" target="_blank">28240446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27407013">
<a name="27407013"></a>Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. <i>Diabetes Obes Metab</i>. 2016;18(12):1199-1206. doi:10.1111/dom.12742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/27407013/pubmed" id="27407013" target="_blank">27407013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26086329">
<a name="26086329"></a>Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2849-2852. doi:10.1210/jc.2015-1884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/26086329/pubmed" id="26086329" target="_blank">26086329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30429124">
<a name="30429124"></a>Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. <i>BMJ</i>. 2018;363:k4365. doi:10.1136/bmj.k4365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30429124/pubmed" id="30429124" target="_blank">30429124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.6">
<a name="FDA.6"></a>US Food and Drug Administration (FDA). FDA drug safety communication: FDA confirms increasedrisk of leg and foot amputations with the diabetes medicinecanagliozin (Invokana, Invokamet, Invokamet XR). <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine</a>. Updated July 2017. Accessed March 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Food and Drug Administration. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin</a>. Published June 14, 2016. Updated June 17, 2016. Accessed October 11, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30131409">
<a name="30131409"></a>van Niekerk C, Wallace J, Takata M, Yu R. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin [published online August 20, 2018]. <i>BMJ Case Rep</i>. doi:10.1136/bcr-2017-221527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30131409/pubmed" id="30131409" target="_blank">30131409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27048192">
<a name="27048192"></a>Vasapollo P, Cione E, Luciani F, Gallelli L. Generalized intense pruritus during canagliflozin treatment: Is it an adverse drug reaction? <i>Curr Drug Saf</i>. 2018;13(1):38-40. doi:10.2174/1574886311666160405110515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/27048192/pubmed" id="27048192" target="_blank">27048192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26580237">
<a name="26580237"></a>Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. <i>J Clin Endocrinol Metab</i>. 2016;101(1):157-166. doi:10.1210/jc.2015-3167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/26580237/pubmed" id="26580237" target="_blank">26580237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24786834">
<a name="24786834"></a>Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). <i>Curr Med Res Opin</i>. 2014;30(9):1759-1768. doi:10.1185/03007995.2014.919907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/24786834/pubmed" id="24786834" target="_blank">24786834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Management of persistent hyperglycemia in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30415602">
<a name="30415602"></a>Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med</i>. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30415602/pubmed" id="30415602" target="_blank">30415602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30424892">
<a name="30424892"></a>Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i>. 2019;393(10166):31-39. doi:10.1016/S0140-6736(18)32590-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/30424892/pubmed" id="30424892" target="_blank">30424892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31399845">
<a name="31399845"></a>Zhou Z, Jardine M, Perkovic V, et al. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. <i>Diabetologia</i>. 2019;62(10):1854-1867. doi:10.1007/s00125-019-4955-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canagliflozin-drug-information/abstract-text/31399845/pubmed" id="31399845" target="_blank">31399845</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 88901 Version 274.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
